Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Schedule of Revenue Recognition (Details)

v3.23.1
Revenue Recognition - Schedule of Revenue Recognition (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Disaggregation of Revenue [Line Items]    
Total revenue $ 5,433 $ 5,031
Functional neurosurgery navigation and therapy    
Disaggregation of Revenue [Line Items]    
Total revenue 2,361 2,238
Functional Neurosurgery Navigation and Therapy - Disposable Products    
Disaggregation of Revenue [Line Items]    
Total revenue 1,858 1,863
Functional Neurosurgery Navigation and Therapy - Services    
Disaggregation of Revenue [Line Items]    
Total revenue 503 375
Biologics and drug delivery    
Disaggregation of Revenue [Line Items]    
Total revenue 2,676 2,154
Biologics and Drug Delivery - Disposable Products    
Disaggregation of Revenue [Line Items]    
Total revenue 594 850
Biologics and Drug Delivery - Services and license fees    
Disaggregation of Revenue [Line Items]    
Total revenue 2,082 1,304
Capital equipment and software    
Disaggregation of Revenue [Line Items]    
Total revenue 396 639
Capital Equipment and Software - Systems and Software Products    
Disaggregation of Revenue [Line Items]    
Total revenue 178 450
Capital Equipment and Software - Services    
Disaggregation of Revenue [Line Items]    
Total revenue $ 218 $ 189